JP6543259B2 - 選択的ｎｒ２ｂアンタゴニスト - Google Patents
選択的ｎｒ２ｂアンタゴニスト Download PDFInfo
- Publication number
- JP6543259B2 JP6543259B2 JP2016545819A JP2016545819A JP6543259B2 JP 6543259 B2 JP6543259 B2 JP 6543259B2 JP 2016545819 A JP2016545819 A JP 2016545819A JP 2016545819 A JP2016545819 A JP 2016545819A JP 6543259 B2 JP6543259 B2 JP 6543259B2
- Authority
- JP
- Japan
- Prior art keywords
- fluoro
- piperidin
- pyrrolidin
- hydroxyphenyl
- mmol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- CTLORLXXXUKEAR-YADHBBJMSA-N CC(C)(C)OC(N(CC[C@@H]1c(cc2)ccc2OCc2ccccc2)C[C@@H]1OC)=O Chemical compound CC(C)(C)OC(N(CC[C@@H]1c(cc2)ccc2OCc2ccccc2)C[C@@H]1OC)=O CTLORLXXXUKEAR-YADHBBJMSA-N 0.000 description 1
- PWFWQTXCQTXHKI-UGGDCYSXSA-N CC1=CC=C(CN(CCC2N(CC[C@H]3c(cc4)ccc4O)C[C@H]3F)C2=O)CC1 Chemical compound CC1=CC=C(CN(CCC2N(CC[C@H]3c(cc4)ccc4O)C[C@H]3F)C2=O)CC1 PWFWQTXCQTXHKI-UGGDCYSXSA-N 0.000 description 1
- 0 C[C@](*(CCC1C(F)(F)F)C1=O)c(cc1)ccc1N Chemical compound C[C@](*(CCC1C(F)(F)F)C1=O)c(cc1)ccc1N 0.000 description 1
- IESUXIJJIRXKNX-UHFFFAOYSA-N Cc(ccc(CN(CCC1N(C2)CC2c(cc2)ccc2O)C1=O)c1)c1F Chemical compound Cc(ccc(CN(CCC1N(C2)CC2c(cc2)ccc2O)C1=O)c1)c1F IESUXIJJIRXKNX-UHFFFAOYSA-N 0.000 description 1
- YPQRZBTXPBZJBN-HXOQZHHGSA-N Cc(ccc(CN(CCC1N(CC[C@@H]2c(cc3)cc(F)c3O)C[C@@H]2F)C1=O)c1)c1F Chemical compound Cc(ccc(CN(CCC1N(CC[C@@H]2c(cc3)cc(F)c3O)C[C@@H]2F)C1=O)c1)c1F YPQRZBTXPBZJBN-HXOQZHHGSA-N 0.000 description 1
- MGQCKHMKECMTHK-ITAUSPCMSA-N Cc1cc(CN(CCC2N(CC[C@@H]3c(cc4)ccc4O)CC3F)C2=O)ccc1 Chemical compound Cc1cc(CN(CCC2N(CC[C@@H]3c(cc4)ccc4O)CC3F)C2=O)ccc1 MGQCKHMKECMTHK-ITAUSPCMSA-N 0.000 description 1
- BGRHMASKGAZXFJ-UHFFFAOYSA-N Cc1ccc(CN(CCC2N(CC3)CCC3c(cc3)ccc3O)C2=O)cc1C Chemical compound Cc1ccc(CN(CCC2N(CC3)CCC3c(cc3)ccc3O)C2=O)cc1C BGRHMASKGAZXFJ-UHFFFAOYSA-N 0.000 description 1
- UNVYDSCXINFREZ-YPAWHYETSA-N Cc1ccc(CN(CC[C@H]2N(CC[C@@H]3c(cc4)ccc4O)C[C@H]3F)C2=O)cc1 Chemical compound Cc1ccc(CN(CC[C@H]2N(CC[C@@H]3c(cc4)ccc4O)C[C@H]3F)C2=O)cc1 UNVYDSCXINFREZ-YPAWHYETSA-N 0.000 description 1
- UMMNFALVRYANIF-CEWLAPEOSA-N Cc1ccc(CN(CC[C@H]2N(CC[C@H]3c(cc4F)ccc4O)C[C@H]3F)C2=O)cc1 Chemical compound Cc1ccc(CN(CC[C@H]2N(CC[C@H]3c(cc4F)ccc4O)C[C@H]3F)C2=O)cc1 UMMNFALVRYANIF-CEWLAPEOSA-N 0.000 description 1
- NIPVYFDEJFFCLH-GIBKCMNESA-N O[C@H](CN(CC1)C(CCN2Cc(cc3)ccc3F)C2=O)[C@H]1c(cc1)ccc1O Chemical compound O[C@H](CN(CC1)C(CCN2Cc(cc3)ccc3F)C2=O)[C@H]1c(cc1)ccc1O NIPVYFDEJFFCLH-GIBKCMNESA-N 0.000 description 1
- IGCCCAHGRVJMAF-UHFFFAOYSA-N Oc1ccc(C(CC2)CCN2C(CCN2C3c4ccccc4CC3)C2=O)cc1 Chemical compound Oc1ccc(C(CC2)CCN2C(CCN2C3c4ccccc4CC3)C2=O)cc1 IGCCCAHGRVJMAF-UHFFFAOYSA-N 0.000 description 1
- PNHIUDSSYHTHOT-UHFFFAOYSA-N Oc1ccc(C(CC2)CCN2C(CCN2Cc(cc3)ccc3OC(F)F)C2=O)cc1 Chemical compound Oc1ccc(C(CC2)CCN2C(CCN2Cc(cc3)ccc3OC(F)F)C2=O)cc1 PNHIUDSSYHTHOT-UHFFFAOYSA-N 0.000 description 1
- PHBBGHAXNTZALA-UHFFFAOYSA-N Oc1ccc(C(CC2)CCN2C(CCN2Cc3ccccc3)C2=O)cc1 Chemical compound Oc1ccc(C(CC2)CCN2C(CCN2Cc3ccccc3)C2=O)cc1 PHBBGHAXNTZALA-UHFFFAOYSA-N 0.000 description 1
- FGYWBVVJUUWCLN-UHFFFAOYSA-N Oc1ccc(C(CC2)CCN2C(CCN2Cc3ccccc3)C2=O)cc1F Chemical compound Oc1ccc(C(CC2)CCN2C(CCN2Cc3ccccc3)C2=O)cc1F FGYWBVVJUUWCLN-UHFFFAOYSA-N 0.000 description 1
- KOQYBHVHTCKDIZ-NRFANRHFSA-N Oc1ccc(C(CC2)CCN2[C@@H](CCN2Cc(cc3)ccc3F)C2=O)cc1 Chemical compound Oc1ccc(C(CC2)CCN2[C@@H](CCN2Cc(cc3)ccc3F)C2=O)cc1 KOQYBHVHTCKDIZ-NRFANRHFSA-N 0.000 description 1
- KOQYBHVHTCKDIZ-OAQYLSRUSA-N Oc1ccc(C(CC2)CCN2[C@H](CCN2Cc(cc3)ccc3F)C2=O)cc1 Chemical compound Oc1ccc(C(CC2)CCN2[C@H](CCN2Cc(cc3)ccc3F)C2=O)cc1 KOQYBHVHTCKDIZ-OAQYLSRUSA-N 0.000 description 1
- NCAFFUYLUZFZJF-UHFFFAOYSA-N Oc1ccc(C(CCC2)CCN2C(CCN2Cc3ccccc3)C2=O)cc1 Chemical compound Oc1ccc(C(CCC2)CCN2C(CCN2Cc3ccccc3)C2=O)cc1 NCAFFUYLUZFZJF-UHFFFAOYSA-N 0.000 description 1
- UMACWEJWGGYMLA-DAFXYXGESA-N Oc1ccc(C(CCN(C2)[C@@H](CCN3c(cc4Cl)ccc4OC(F)F)C3=O)C2(F)F)cc1 Chemical compound Oc1ccc(C(CCN(C2)[C@@H](CCN3c(cc4Cl)ccc4OC(F)F)C3=O)C2(F)F)cc1 UMACWEJWGGYMLA-DAFXYXGESA-N 0.000 description 1
- GXCCYLLPBRUNGP-UHFFFAOYSA-N Oc1ccc(C(CCNC2)C2(F)F)cc1 Chemical compound Oc1ccc(C(CCNC2)C2(F)F)cc1 GXCCYLLPBRUNGP-UHFFFAOYSA-N 0.000 description 1
- HHJUWULCHBPNME-PDYHCXRVSA-N Oc1ccc([C@@H](CCN(C2)C(CCN3Cc(cc4)ccc4OC(F)F)C3=O)[C@H]2F)cc1 Chemical compound Oc1ccc([C@@H](CCN(C2)C(CCN3Cc(cc4)ccc4OC(F)F)C3=O)[C@H]2F)cc1 HHJUWULCHBPNME-PDYHCXRVSA-N 0.000 description 1
- JATJVTHLUABLLD-QMMLZNLJSA-N Oc1ccc([C@@H](CCN(C2)[C@@H](CCN3Cc(cc4)cc(F)c4Cl)C3=O)[C@H]2F)cc1 Chemical compound Oc1ccc([C@@H](CCN(C2)[C@@H](CCN3Cc(cc4)cc(F)c4Cl)C3=O)[C@H]2F)cc1 JATJVTHLUABLLD-QMMLZNLJSA-N 0.000 description 1
- XECUJMAUWGIGPW-UXHICEINSA-N Oc1ccc([C@@H](CCN(C2)[C@@H](CCN3Cc(cc4)ccc4F)C3=O)C2(F)F)cc1 Chemical compound Oc1ccc([C@@H](CCN(C2)[C@@H](CCN3Cc(cc4)ccc4F)C3=O)C2(F)F)cc1 XECUJMAUWGIGPW-UXHICEINSA-N 0.000 description 1
- XECUJMAUWGIGPW-WOJBJXKFSA-N Oc1ccc([C@@H](CCN(C2)[C@H](CCN3Cc(cc4)ccc4F)C3=O)C2(F)F)cc1 Chemical compound Oc1ccc([C@@H](CCN(C2)[C@H](CCN3Cc(cc4)ccc4F)C3=O)C2(F)F)cc1 XECUJMAUWGIGPW-WOJBJXKFSA-N 0.000 description 1
- HGAPKINVUOUWJG-GHMZBOCLSA-N Oc1ccc([C@@H](CCNC2)[C@@H]2F)cc1 Chemical compound Oc1ccc([C@@H](CCNC2)[C@@H]2F)cc1 HGAPKINVUOUWJG-GHMZBOCLSA-N 0.000 description 1
- FDBBJNOKPFRGFR-DVUUQMMQSA-N Oc1ccc([C@H](CCN(C2)C(CCN3Cc(cc4)cc(Cl)c4F)C3=O)[C@@H]2F)cc1 Chemical compound Oc1ccc([C@H](CCN(C2)C(CCN3Cc(cc4)cc(Cl)c4F)C3=O)[C@@H]2F)cc1 FDBBJNOKPFRGFR-DVUUQMMQSA-N 0.000 description 1
- GEARHVGBHFRSBG-DVUUQMMQSA-N Oc1ccc([C@H](CCN(C2)C(CCN3Cc(cc4)cc(F)c4F)C3=O)[C@@H]2F)cc1 Chemical compound Oc1ccc([C@H](CCN(C2)C(CCN3Cc(cc4)cc(F)c4F)C3=O)[C@@H]2F)cc1 GEARHVGBHFRSBG-DVUUQMMQSA-N 0.000 description 1
- XECUJMAUWGIGPW-PMACEKPBSA-N Oc1ccc([C@H](CCN(C2)[C@@H](CCN3Cc(cc4)ccc4F)C3=O)C2(F)F)cc1 Chemical compound Oc1ccc([C@H](CCN(C2)[C@@H](CCN3Cc(cc4)ccc4F)C3=O)C2(F)F)cc1 XECUJMAUWGIGPW-PMACEKPBSA-N 0.000 description 1
- QGVLIVYFBAIXBS-SXLOBPIMSA-N Oc1ccc([C@H](CCN(C2)[C@@H](CCN3Cc4ccc(C(F)F)cc4)C3=O)[C@@H]2F)cc1F Chemical compound Oc1ccc([C@H](CCN(C2)[C@@H](CCN3Cc4ccc(C(F)F)cc4)C3=O)[C@@H]2F)cc1F QGVLIVYFBAIXBS-SXLOBPIMSA-N 0.000 description 1
- XECUJMAUWGIGPW-VQTJNVASSA-N Oc1ccc([C@H](CCN(C2)[C@H](CCN3Cc(cc4)ccc4F)C3=O)C2(F)F)cc1 Chemical compound Oc1ccc([C@H](CCN(C2)[C@H](CCN3Cc(cc4)ccc4F)C3=O)C2(F)F)cc1 XECUJMAUWGIGPW-VQTJNVASSA-N 0.000 description 1
- XFXAVVJYLLLZPG-PWRODBHTSA-N Oc1ccc([C@H](CCN(C2)[C@H](CCN3Cc(cc4)ccc4F)C3=O)[C@@H]2F)cc1 Chemical compound Oc1ccc([C@H](CCN(C2)[C@H](CCN3Cc(cc4)ccc4F)C3=O)[C@@H]2F)cc1 XFXAVVJYLLLZPG-PWRODBHTSA-N 0.000 description 1
- ZINNJNWQBUSWGG-QXAKKESOSA-N Oc1ccc([C@H](CCN(C2)[C@H](CCN3c(cc4)cc(Cl)c4OC(F)F)C3=O)[C@@H]2F)cc1 Chemical compound Oc1ccc([C@H](CCN(C2)[C@H](CCN3c(cc4)cc(Cl)c4OC(F)F)C3=O)[C@@H]2F)cc1 ZINNJNWQBUSWGG-QXAKKESOSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461925363P | 2014-01-09 | 2014-01-09 | |
| US61/925,363 | 2014-01-09 | ||
| PCT/US2015/010262 WO2015105772A1 (en) | 2014-01-09 | 2015-01-06 | Selective nr2b antagonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017502063A JP2017502063A (ja) | 2017-01-19 |
| JP2017502063A5 JP2017502063A5 (enExample) | 2018-02-08 |
| JP6543259B2 true JP6543259B2 (ja) | 2019-07-10 |
Family
ID=52463126
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016545819A Expired - Fee Related JP6543259B2 (ja) | 2014-01-09 | 2015-01-06 | 選択的ｎｒ２ｂアンタゴニスト |
Country Status (28)
| Country | Link |
|---|---|
| US (10) | US9221796B2 (enExample) |
| EP (1) | EP3092224B1 (enExample) |
| JP (1) | JP6543259B2 (enExample) |
| KR (1) | KR102311518B1 (enExample) |
| CN (1) | CN106061961B (enExample) |
| AR (1) | AR099071A1 (enExample) |
| AU (1) | AU2015205001A1 (enExample) |
| CA (1) | CA2936293A1 (enExample) |
| CL (1) | CL2016001763A1 (enExample) |
| DK (1) | DK3092224T3 (enExample) |
| EA (1) | EA201691413A1 (enExample) |
| ES (1) | ES2693250T3 (enExample) |
| HR (1) | HRP20181585T1 (enExample) |
| HU (1) | HUE041986T2 (enExample) |
| IL (1) | IL246599A0 (enExample) |
| LT (1) | LT3092224T (enExample) |
| MX (1) | MX2016008898A (enExample) |
| PE (1) | PE20160933A1 (enExample) |
| PL (1) | PL3092224T3 (enExample) |
| PT (1) | PT3092224T (enExample) |
| RS (1) | RS57830B1 (enExample) |
| SG (1) | SG11201605618WA (enExample) |
| SI (1) | SI3092224T1 (enExample) |
| SM (1) | SMT201800619T1 (enExample) |
| TR (1) | TR201815579T4 (enExample) |
| TW (1) | TWI640515B (enExample) |
| UY (1) | UY35947A (enExample) |
| WO (1) | WO2015105772A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9221796B2 (en) * | 2014-01-09 | 2015-12-29 | Bristol-Myers Squibb Company | Selective NR2B antagonists |
| EP3303323B1 (en) * | 2015-06-01 | 2020-01-08 | Rugen Holdings (Cayman) Limited | 3,3-difluoropiperidine carbamate heterocyclic compounds as nr2b nmda receptor antagonists |
| AU2016340237A1 (en) * | 2015-10-14 | 2018-05-31 | Bristol-Myers Squibb Company | Selective NR2B antagonists |
| CA3001894A1 (en) | 2015-10-14 | 2017-04-20 | Bristol-Myers Squibb Company | Selective nr2b antagonists |
| CN108203404A (zh) * | 2018-03-02 | 2018-06-26 | 上海博邦医药科技有限公司 | (r)-3-苯基哌啶或/和(s)-3-苯基哌啶以及尼拉帕尼的手性中间体的合成方法 |
| US10781172B2 (en) | 2018-06-21 | 2020-09-22 | Northwestern University | Catalysts and methods for enantioselective conjugate additions of amines to unsaturated electrophiles |
| WO2024197289A1 (en) * | 2023-03-22 | 2024-09-26 | Gilgamesh Pharmaceuticals, Inc. | Negative allosteric modulators of glun2b receptors and methods of making and using the same |
| CN119504546B (zh) * | 2023-11-28 | 2025-12-05 | 成都地奥制药集团有限公司 | 内酰胺环类化合物及其用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2744448B1 (fr) | 1996-02-02 | 1998-04-24 | Pf Medicament | Nouvelles piperidines derivees d'aryl piperazine, ainsi que leur procede de preparation, les compositions pharmaceutiques et leur utilisation comme medicaments |
| WO2000063173A1 (en) | 1999-04-14 | 2000-10-26 | F. Hoffmann-La Roche Ag | Process for the preparation of substituted piperidines |
| US6476041B1 (en) | 1999-10-29 | 2002-11-05 | Merck & Co., Inc. | 1,4 substituted piperidinyl NMDA/NR2B antagonists |
| ATE337292T1 (de) | 2000-04-26 | 2006-09-15 | Warner Lambert Co | Trans-n- 4-(4-hydroxyphenyl)cyclohexylö-3- phenylpropionamid als subtyp-selektiver nmda rezeptor antagonist |
| WO2003035641A1 (en) | 2001-10-22 | 2003-05-01 | Shionogi & Co., Ltd. | Novel carbamoylpyrrolidone derivative |
| CN1798744A (zh) | 2003-06-04 | 2006-07-05 | 麦克公司 | 作为nmda/nr2b拮抗剂的3－氟－哌啶化合物 |
| BRPI0415113A (pt) | 2003-10-08 | 2006-11-28 | Pfizer | compostos de lactama condensados |
| US7935706B2 (en) | 2006-02-23 | 2011-05-03 | Shionogi & Co., Ltd. | Nitrogen-containing heterocycle derivatives substituted with cyclic group |
| EP2170334B1 (en) | 2007-06-29 | 2021-03-17 | Emory University | Nmda receptor antagonists for neuroprotection |
| US9221796B2 (en) * | 2014-01-09 | 2015-12-29 | Bristol-Myers Squibb Company | Selective NR2B antagonists |
-
2015
- 2015-01-05 US US14/589,205 patent/US9221796B2/en active Active
- 2015-01-06 HR HRP20181585TT patent/HRP20181585T1/hr unknown
- 2015-01-06 PT PT15703328T patent/PT3092224T/pt unknown
- 2015-01-06 DK DK15703328.3T patent/DK3092224T3/en active
- 2015-01-06 PL PL15703328T patent/PL3092224T3/pl unknown
- 2015-01-06 MX MX2016008898A patent/MX2016008898A/es unknown
- 2015-01-06 LT LTEP15703328.3T patent/LT3092224T/lt unknown
- 2015-01-06 SI SI201530408T patent/SI3092224T1/sl unknown
- 2015-01-06 CN CN201580012735.9A patent/CN106061961B/zh not_active Expired - Fee Related
- 2015-01-06 PE PE2016001107A patent/PE20160933A1/es not_active Application Discontinuation
- 2015-01-06 JP JP2016545819A patent/JP6543259B2/ja not_active Expired - Fee Related
- 2015-01-06 HU HUE15703328A patent/HUE041986T2/hu unknown
- 2015-01-06 SG SG11201605618WA patent/SG11201605618WA/en unknown
- 2015-01-06 CA CA2936293A patent/CA2936293A1/en not_active Abandoned
- 2015-01-06 EA EA201691413A patent/EA201691413A1/ru unknown
- 2015-01-06 TR TR2018/15579T patent/TR201815579T4/tr unknown
- 2015-01-06 EP EP15703328.3A patent/EP3092224B1/en active Active
- 2015-01-06 AU AU2015205001A patent/AU2015205001A1/en not_active Abandoned
- 2015-01-06 WO PCT/US2015/010262 patent/WO2015105772A1/en not_active Ceased
- 2015-01-06 SM SM20180619T patent/SMT201800619T1/it unknown
- 2015-01-06 RS RS20181296A patent/RS57830B1/sr unknown
- 2015-01-06 KR KR1020167021356A patent/KR102311518B1/ko not_active Expired - Fee Related
- 2015-01-06 ES ES15703328.3T patent/ES2693250T3/es active Active
- 2015-01-08 TW TW104100592A patent/TWI640515B/zh not_active IP Right Cessation
- 2015-01-09 UY UY0001035947A patent/UY35947A/es unknown
- 2015-01-09 AR ARP150100065A patent/AR099071A1/es unknown
- 2015-10-13 US US14/882,041 patent/US20160081995A1/en not_active Abandoned
-
2016
- 2016-07-04 IL IL246599A patent/IL246599A0/en unknown
- 2016-07-08 CL CL2016001763A patent/CL2016001763A1/es unknown
-
2017
- 2017-05-25 US US15/604,904 patent/US20170258777A1/en not_active Abandoned
- 2017-09-15 US US15/706,172 patent/US20180000807A1/en not_active Abandoned
- 2017-12-19 US US15/846,672 patent/US20180110766A1/en not_active Abandoned
-
2018
- 2018-05-04 US US15/971,067 patent/US20180250283A1/en not_active Abandoned
- 2018-12-19 US US16/225,850 patent/US20190117638A1/en not_active Abandoned
-
2019
- 2019-06-27 US US16/454,831 patent/US20190314358A1/en not_active Abandoned
-
2020
- 2020-01-30 US US16/777,114 patent/US20200163949A1/en not_active Abandoned
- 2020-09-04 US US17/012,781 patent/US20210121453A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6543259B2 (ja) | 選択的ｎｒ２ｂアンタゴニスト | |
| JP6843853B2 (ja) | 選択的ｎｒ２ｂアンタゴニスト | |
| CA2777041A1 (en) | Pyrrolidine gpr40 modulators | |
| JP6629738B2 (ja) | 精神障害の治療のための（ｒ）−３−（（３ｓ，４ｓ）−３−フルオロ−４−（４−ヒドロキシフェニル）ピペリジン−１−イル）−１−（４−メチルベンジル）ピロリジン−２−オンおよびそのプロドラッグ | |
| ES2668873T3 (es) | Compuestos de indazol como agonistas del receptor 5-ht4 | |
| JP6938485B2 (ja) | 選択的ｎｒ２ｂアンタゴニスト |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171225 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20171225 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20180816 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180821 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20181120 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181227 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190521 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190614 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6543259 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |